| アブストラクト | INTRODUCTION: Respiratory syncytial virus (RSV) causes significant disease in older and comorbid adults. Current UK vaccination recommendations restrict eligibility to adults >/= 75 years, 65-74 years with chronic respiratory disease or immunosuppression, and those in care homes, but evidence on clinical burden in adults < 75 years with comorbidities is limited. This study assessed patient characteristics, healthcare resource utilization (HCRU), and mortality in adults hospitalized with RSV in England. METHODS: Population-based retrospective cohort study using linked Clinical Practice Research Datalink Aurum and Hospital Episode Statistics. Adults >/= 60 years hospitalized with RSV between October 2014 and March 2019 were included. We defined RSV episodes as 90 days post-diagnosis. We defined cases using diagnosis codes for confirmed RSV (RSV-specific) or acute lower respiratory tract infection with exclusion of other causative pathogens (RSV-possible). All-cause HCRU (hospitalizations, critical care admissions, outpatient attendance, primary care consultations, and prescriptions) and case fatality rates were assessed. Results were stratified by age (60-74 and >/= 75 years), case definitions (RSV-specific, RSV-possible), and comorbidity profiles (chronic respiratory disease, immunocompromised, cardiovascular disease). RESULTS: A total of 97,712 hospitalized episodes in those aged >/= 60 years were included in the analysis, of which 785 (0.8%) were RSV-specific cases (n = 338 aged 60-74 years, n = 447 aged >/= 75 years). In RSV-specific cases, median (IQR) cumulative length of stay (LoS) for those >/= 75 years was 10.00 (6.00-22.00) days, which was equivalent to or lower than each comorbidity subgroup in those aged 60-74 years, with the longest LoS in those immunocompromised (11.50 [7.00-26.00] days). Critical care admissions were more often observed across comorbidity stratifications (13.85-22.34%) compared to those >/= 75 years (5.03%). All-cause and RSV-related case fatality rates for RSV-specific cases were highest among those >/= 75 years (all-cause: 19.3%; RSV-related: 10.3%). CONCLUSIONS: HCRU within RSV episodes in those aged 60-74 years across comorbidity profiles was equal to or greater than that in those aged >/= 75 years. These findings highlight the need to prioritize consideration of comorbidity groups that could benefit from RSV vaccination. |
|---|
| ジャーナル名 | Infectious diseases and therapy |
|---|
| Pubmed追加日 | 2026/10/6 |
|---|
| 投稿者 | Butfield, Rebecca; Rai, Kiran K; Jennison, Thomas; Said, Jack; Wright, Hannah; Sethi, Dheeraj; Watkins, Jonathan; Geneidat, Antonia; Jimenez, Isabel; Wiseman, Dexter |
|---|
| 組織名 | Access & Value, Pfizer Ltd, Tadworth, UK. rebecca.butfield@pfizer.com.;Real-World Evidence, Adelphi Real World, Bollington, Cheshire, UK.;Access & Value, Pfizer Ltd, Tadworth, UK.;National Heart and Lung Institute, Imperial College London, London, UK.;Chelsea and Westminster National Health Service Foundation Trust, London, UK. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/42836949/ |
|---|
